5-Fluorouracil
1 clinical trial
31 abstracts
1 indication
Indication
Locally Advanced Rectal CancerAbstract
A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatment-naïve metastatic pancreatic cancer (GIANT): ECOG-ACRIN EA2186.Org: Fox Chase Cancer Center, Dana-Farber Cancer Institute, Wake Forest University Department of General Internal Medicine, Stanford University School of Medicine, ThedaCare Regional Medical Center,
Abstract
FU/FA maintenance therapy with or without panitumumab (pmab) in RAS wild-type metastatic colorectal cancer (mCRC) (PanaMa, AIO KRK 0212): Updated efficacy analyses.Org: Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Klinik Dr. Hancken GmbH,
Abstract
Retrospective analysis: Does 5-FU dose adjustment per DPYD mutation status affect toxicity?Org: SUNY Upstate Medical University, Tata Memorial Centre, Hinduja Hospital, Tata Memorial Hospital,
Abstract
Neoadjuvant dual checkpoint inhibition followed by immune-chemoradiation in patients with resectable gastric adenocarcinoma.Org: Department of Gastroenterology, Hepatology, and Nutrition University of Texas MD Anderson Cancer Center,
Abstract
Modulation of lipid metabolism associated with response to metronomic capecitabine plus camrelizumab in patients with refractory gastrointestinal cancer: A prospective, single-center, exploratory trial.Org: Department of Oncology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, Key Laboratory of Systems Health Science of Zhejiang Province, School of Life Science, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou, China, Department of Oncology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China, Shanghai Institute of Digestive Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, Department of Radiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China,
Abstract
A modular, open-label, phase I/IIa study to evaluate the safety, tolerability, pharmacokinetics (PKs) and anti-tumour activity of a first-in-class (FIC) specific dUTPase inhibitor CV6-168 combined with anti-cancer treatments in patients (pts) with advanced malignancies.Org: Newcastle University and Northern Centre for Cancer Care, University of Sheffield, CV6 Therapeutics (NI) Ltd, Newcastle University and Northern Centre for Cancer Care, Newcastle Hospitals NHS Trust,
Abstract
CLARITY-PanTumor01: A phase 2 trial of the claudin 18.2-specific antibody-drug conjugate AZD0901 (CMG901) in patients with CLDN18.2-expressing advanced solid tumors.Org: Global Medicines Development,
Abstract
Neoadjuvant chemotherapy with FOLFOXIRI plus lateral lymph nodes dissection for the treatment of resectable rectal cancer with lateral lymph node metastasis: A single-arm, investigator-initiated, phase II trial.Org: State Key Laboratory of Molecular Oncology and Department of Radiation Oncology, Comprehensive Third Ward, Cancer Institute & Hospital,
Abstract
NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naïve patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): Updated overall survival analysis with 29-month follow-up of NAPOLI 3.Org: Florida Cancer Specialists North Division, Gastrointestinal and Endocrine Tumor Unit Vall d'Hebron University Hospital and Vall d'Hebrón Institute of Oncology (VHIO), IPSEN Bioinnovation Limited, Università degli studi di Verona and Azienda Ospedaliera Universitaria Integrata,
Abstract
Apatinib and camrelizumab plus Intravenous FOLFOX or hepatic arterial infusion chemotherapy with FOLFOX for advanced HCC: A multicenter, prospective, randomized phase III trial.Org: Department of Hepatobiliary Surgery, Qilu Hospital of Shandong University, Jinan, China, Sun Yat-sen Memorial Hospital, Sun Yat-sen University Cancer Center Gansu Hospital, Department of Breast Cancer, Hubei Cancer Hospital, Wuhan, China, Department of Radiology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China,
Abstract
Updated results from venous infusion chemotherapy (VIC) plus apatinib and camrelizumab for hepatocellular carcinoma (HCC) in CNLC stage III: A prospective, single-arm, phase II trial.Org: Department of Hepatobiliary Surgery,
Abstract
Apatinib and camrelizumab plus hepatic arterial infusion with oxaliplatin and 5-fluorouracil vs. apatinib and camrelizumab as the first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A randomized multi-center clinical trial.Org: Department of Hepatobiliary Oncology, Liver Cancer Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China, Sun Yat-sen University Cancer Center Gansu Hospital, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China,
Abstract
SAVE: A prospective, single-arm, single-center clinical study of disitamab vedotin in combination with toripalimab in patients with advanced penile cancer that has progressed or is intolerant to cisplatin chemotherapy.Org: Affiliated Cancer Hospital of Chongqing University,
Abstract
Neoadjuvant/adjuvant pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo for gastric/gastroesophageal junction (G/GEJ) adenocarcinoma: Major pathologic response (mPR) in KEYNOTE-585.Org: Chonnam National University Medical School, Hwasun, South Korea, Veneto Institute of Oncology IOV–IRCCS, Padua, Italy, Universidad de La Frontera, James Lind Cancer Research Center, Temuco, Chile, National Cheng Kung University, Tainan, Taiwan, CHU Brest–Institut de Cancerologie et d’Hematologie ARPEGO Network, Brest, France,
Abstract
A phase II study of cadonilimab plus mFOLFIRINOX as induction therapy for locally advanced pancreatic adenocarcinoma (LAPC).Org: Nanjing, China, Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital,
Abstract
Alliance EAY191-A6: FOLFOX in combination with binimetinib as second-line therapy for patients with advanced biliary tract cancers (BTCs) with MAPK pathway alterations: A ComboMATCH treatment trial.Org: The Ohio State University Wexner Medical Center and Comprehensive Cancer Center, Trinity Health IHA Medical Group,
Abstract
Sequential neoadjuvant chemotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma.Org: Atrium Health Wake Forest University Baptist Medical Center,
Abstract
Dendrimer-enhanced (DEP) SN38 (DEP irinotecan) in patients (pts) with advanced solid tumors: A phase 1/2 trial.Org: Royal Marsden/Institute of Cancer Research, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Sir Bobby Robson Cancer Trial Research Centre,
Abstract
A phase 1/2, safety lead-in and dose expansion, open-label, multicenter trial investigating the safety, tolerability, and preliminary activity of ivosidenib in combination with nivolumab and ipilimumab in previously treated subjects with IDH1-mutated nonresectable or metastatic cholangiocarcinoma.Org: Servier Pharmaceuticals LLC,
Abstract
Hepatic artery infusion chemotherapy combined with immune checkpoint inhibitors and tyrosine kinase inhibitors for advanced hepatocellular carcinoma with portal vein tumor thrombus: A single center retrospective study.Org: Department II of Interventional Radiology,
Abstract
Efficacy of oncolytic virus combined with HAIC of mFOLFOX for IMCC: A single-center, single-arm, prospective study.Org: Hepatobiliary Pancreatic Center Department,
Abstract
A randomised phase 2 study of liposomal irinotecan in combination with 5-fluorouracil/leucovorin and oxalipalatin versus nab-paclitaxel plus gemcitabine in unresectable locally advanced or metastatic pancreatic cancer.Org: Liaoning Cancer Hospital, Shenyang, China, Affiliated Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, Yunnan Cancer Hospital, Yunnan, China, CSPC Ouyi Pharmaceutical Technology (Shijiazhuang) Co.,Ltd, Shijiazhuang, China,
Abstract
Development and validation of AI-assisted transcriptomic signatures to personalize adjuvant chemotherapy in patients with resectable pancreatic ductal adenocarcinoma.Org: Cancer Research Center of Marseille (CRCM), Digestive and Medical Oncology Department, Paul Brousse Hospital, Cancer Centre of Southeastern Ontario/Queen's University, Paoli-Calmettes Institute,
Abstract
Effect of nivolumab combined with definitive chemoradiotherapy on response rate for esophageal cancer: An immune active intrinsic subtype could be its biomarker—The NOBEL trial.Org: Gradyate School of Medicine, Department of Radiation Oncology and Image-Applied Therapy, Department of Therepeutic Oncology, Department of Clinical Trial Promotion, Clinical Trial Promotion Department,
Abstract
A phase II study of liposomal irinotecan-based chemotherapy with or without PD-1 inhibitor in patients with unresectable locally advanced or metastatic biliary tract cancer.Org: Zhejiang Chinese Medical University,
Abstract
Modifying the gastric tumor microenvironment with tadalafil: A transcriptomic analysis of immune signatures from underserved patients of southern Arizona.Org: The University of Arizona Cancer Center, University of Arizona Cancer Center, University of Arizona College of Medicine, Phoenix, AZ,
Abstract
A real-world experience of hepatic arterial infusion chemotherapy combined with tislelizumab and lenvatinib for unresectable hepatocellular carcinoma with type IV portal vein tumor thrombus.Org: Department II of Interventional Radiology,
Abstract
FOLFOX-based hepatic arterial infusion chemotherapy combined with regorafenib for unresectable colorectal liver metastases.Org: Hubei Province Key Laboratory of Molecular Imaging,
Abstract
Patient-derived 3D bioprinting pan-cancer drug screening platform for personalized medicine.Org: Department of Liver Surgery, Peking Union Medical College Hospital, Beijing, China, Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Beijing, China, Department of Physiology, Institute of Basic Medical Sciences, CAMS, Beijing, China, Department of Neurosurgery, Peking Union Medical College Hospital, Beijing, China, Department of Head and Neck Surgical Oncology, Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China,
Abstract
De-escalation treatment of patients with HPV-positive oropharyngeal squamous cell carcinoma.Org: State Medical Institution "City Clinical Oncological Hospital № 1"," Moscow, Russian Federation, P. Hertsen Moscow Oncology Research Institute - Branch of the National Medical Radiology Research Centre of the Ministry of Health of the Russian Federation, Moscow, Russian Federation, City Clinical Cancer Hospital No. 1, Moscow, Russian Federation, Moscow City Clinical Oncology Hospital No. 1, Moscow, Russian Federation, State Medical Institution "S. Yudina Сity Clinical Hospital", Moscow, Russian Federation,
Abstract
Preventing 5-fluorouracil-induced ischemic events in very high-risk cardiac patients: A retrospective cohort analysis (SQCCCRC protocol).Org: Oman,
Clinical trial
Phase II Study of Short-course Radiotherapy Followed by Consolidation Chemotherapy With the Triplet FOLFOXIRI as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: the ShorTrip StudyStatus: Active (not recruiting), Estimated PCD: 2024-05-30